Targets expressed in all myeloma patients show high inter-patient variation, e.g., 6.8 (CD38), 6.9 (BCMA), 9.9 (GPRC5D), and 10.9 (FCRH5) log-fold variation (Figure 1, Table 2). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.